IBDEI2EZ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40953,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,40954,0)
 ;;=E10.59^^159^1996^4
 ;;^UTILITY(U,$J,358.3,40954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40954,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,40954,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,40954,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,40955,0)
 ;;=E10.618^^159^1996^5
 ;;^UTILITY(U,$J,358.3,40955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40955,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,40955,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,40955,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,40956,0)
 ;;=E10.621^^159^1996^7
 ;;^UTILITY(U,$J,358.3,40956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40956,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,40956,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,40956,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,40957,0)
 ;;=E10.622^^159^1996^11
 ;;^UTILITY(U,$J,358.3,40957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40957,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,40957,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,40957,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,40958,0)
 ;;=E10.65^^159^1996^10
 ;;^UTILITY(U,$J,358.3,40958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40958,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,40958,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,40958,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,40959,0)
 ;;=E10.39^^159^1996^9
 ;;^UTILITY(U,$J,358.3,40959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40959,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,40959,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,40959,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,40960,0)
 ;;=E66.3^^159^1996^45
 ;;^UTILITY(U,$J,358.3,40960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40960,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,40960,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,40960,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,40961,0)
 ;;=E89.1^^159^1996^49
 ;;^UTILITY(U,$J,358.3,40961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40961,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,40961,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,40961,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,40962,0)
 ;;=H40.9^^159^1997^9
 ;;^UTILITY(U,$J,358.3,40962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40962,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,40962,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,40962,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,40963,0)
 ;;=H26.9^^159^1997^5
 ;;^UTILITY(U,$J,358.3,40963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40963,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,40963,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,40963,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,40964,0)
 ;;=H10.9^^159^1997^8
 ;;^UTILITY(U,$J,358.3,40964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40964,1,3,0)
 ;;=3^Conjunctivitis,Unspec
 ;;^UTILITY(U,$J,358.3,40964,1,4,0)
 ;;=4^H10.9
 ;;^UTILITY(U,$J,358.3,40964,2)
 ;;=^5004716
 ;;^UTILITY(U,$J,358.3,40965,0)
 ;;=H11.32^^159^1997^6
 ;;^UTILITY(U,$J,358.3,40965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40965,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Left Eye
 ;;^UTILITY(U,$J,358.3,40965,1,4,0)
 ;;=4^H11.32
 ;;^UTILITY(U,$J,358.3,40965,2)
 ;;=^5004783
 ;;^UTILITY(U,$J,358.3,40966,0)
 ;;=H11.31^^159^1997^7
 ;;^UTILITY(U,$J,358.3,40966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40966,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Right Eye
 ;;^UTILITY(U,$J,358.3,40966,1,4,0)
 ;;=4^H11.31
 ;;^UTILITY(U,$J,358.3,40966,2)
 ;;=^5004782
